AbbVie Inc. (ABBV)

74.59
0.09 0.12
NYSE : Health Technology
Prev Close 74.50
Open 74.38
Day Low/High 74.34 / 74.98
52 Wk Low/High 62.66 / 94.98
Volume 3.10M
Avg Volume 8.68M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 109.05B
EPS 3.70
P/E Ratio 26.25
Div & Yield 4.28 (5.66%)
Allergan Reaches Settlement With Ohio Plaintiffs in Federal Opioid Litigation

Allergan Reaches Settlement With Ohio Plaintiffs in Federal Opioid Litigation

Allergan announces it has reached a settlement with two plaintiffs in Ohio in the multi-district federal litigation over opioids.

A Drug Giant, a Media Monolith and Other Stocks That Look Good Short

GLW, ABBV, CBS, LEA and IFF all recently were downgraded by TheStreet's Quant Ratings.

AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer

Rova-T failed to show a survival benefit for patients when compared with a placebo.

AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research And Development Program

AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research And Development Program

- MERU, a Phase 3 placebo-controlled trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit for patients receiving Rova-T at the interim analysis

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: LPG, MCD, SBT, SRTS, WH Downgrades: ABBV, ATRO, EVRI, GLW, GRBK, GVA, IP, MGPI, MMSI, RAND, TEX Initiations: FOCS, LQDA, RVI, TENB Read on to get TheStreet Quant Ratings' detailed report:

AbbVie To Present At The Morgan Stanley Healthcare Conference

AbbVie To Present At The Morgan Stanley Healthcare Conference

NORTH CHICAGO, Ill., Aug.

Analyst Favorites With Strong Buyback Activity: AbbVie Ranks As A Top Pick

Analyst Favorites With Strong Buyback Activity: AbbVie Ranks As A Top Pick

A study of analyst recommendations at the major brokerages shows that AbbVie Inc is the #84 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

Union Pacific, Pfizer, Merck, AbbVie: 'Mad Money' Lightning Round

Union Pacific, Pfizer, Merck, AbbVie: 'Mad Money' Lightning Round

Jim Cramer takes a look at Union Pacific, Pfizer, Merck, AbbVie, Teva Pharmaceuticals, ABM Industries, Schlumberger and more.

Cannabis Stocks Fall: Tilray Up 10.4%; General Cannabis Off 5.3%

Cannabis Stocks Fall: Tilray Up 10.4%; General Cannabis Off 5.3%

Tilray shares pop on first contract to deliver medical marijuana in Europe.

AbbVie Receives FDA Approval Of RINVOQ™ (upadacitinib), An Oral JAK Inhibitor For The Treatment Of Moderate To Severe Rheumatoid Arthritis

AbbVie Receives FDA Approval Of RINVOQ™ (upadacitinib), An Oral JAK Inhibitor For The Treatment Of Moderate To Severe Rheumatoid Arthritis

- RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis[1-7]

Tesla Short-Sellers Are Up Some $3 Billion So Far in 2019

Tesla Short-Sellers Are Up Some $3 Billion So Far in 2019

That's the most successful short position so far this year.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.

Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

Allergan posted stronger-than-expected second quarter earnings Tuesday, and re-affirmed its full-year profit guidance, after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie in late June.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

AbbVie Submits New Drug Application To US FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

AbbVie Submits New Drug Application To US FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients

Putting Amgen's Q2 Earnings Under the Microscope

Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.

Dollar Tree, Newmont Mining, AbbVie: 'Mad Money' Lightning Round

Dollar Tree, Newmont Mining, AbbVie: 'Mad Money' Lightning Round

Jim Cramer takes a look at Dollar Tree, Newmont Mining, AbbVie, Valley National Bancorp, Six Flags, DXC Technology, IBM and more.

Don't Fight the Fed: Cramer's 'Mad Money' Recap (Monday 7/29/19)

Don't Fight the Fed: Cramer's 'Mad Money' Recap (Monday 7/29/19)

Jim Cramer talks about what investors need to do ahead of an expected rate cut and amid earnings and trade upheaval.

AbbVie Rises on Strong Second-Quarter Results, Raised Guidance

AbbVie Rises on Strong Second-Quarter Results, Raised Guidance

Shares of drugmaker AbbVie gain after the company posts better-than-expected quarterly earnings and raises its guidance for the remainder of the year.

Draghi's End Game and a 3-Way Battle Shapes Up in the Cloud: Market Recon

Draghi's End Game and a 3-Way Battle Shapes Up in the Cloud: Market Recon

Plus, Intel results crush expectations and Starbucks solidifies its comeback.

AbbVie Reports Second-Quarter 2019 Financial Results

AbbVie Reports Second-Quarter 2019 Financial Results

- Announced a Definitive Transaction Agreement to Acquire Allergan, Significantly Expanding and Diversifying AbbVie's Revenue Base with New Therapeutic Areas and Enhancing Long-Term R&D Funding Capacity to Allow for Continued Investment in Innovative Science

Amazon, Alphabet, McDonald's, Twitter and U.S. GDP - 5 Things You Must Know

Amazon, Alphabet, McDonald's, Twitter and U.S. GDP - 5 Things You Must Know

U.S. stock futures are rising following earnings reports from tech giants Amazon, Alphabet and Intel and as Wall Street looks ahead to the release of data on U.S. economic growth; Amazon falls after earnings miss forecasts; Alphabet jumps after an earnings beat and the parent of Google says it will buy back $25 billion of stock.

McDonald's, AbbVie, and Twitter - Earnings to Watch

McDonald's, AbbVie, and Twitter - Earnings to Watch

It's Fri-yay, July 26! From McDonald's to Twitter, here's what to watch.

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Earnings Bonanza: Here's What Investors Should Expect in the Week Ahead

Earnings Bonanza: Here's What Investors Should Expect in the Week Ahead

It's a big week for tech earnings, watch the video to see which companies are reporting their quarterly earnings this week.

AbbVie Enhances Early Stage Oncology Pipeline With Acquisition Of Mavupharma

AbbVie Enhances Early Stage Oncology Pipeline With Acquisition Of Mavupharma

NORTH CHICAGO, Ill., July 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon...

AbbVie To Host Second-Quarter 2019 Earnings Conference Call

AbbVie To Host Second-Quarter 2019 Earnings Conference Call

NORTH CHICAGO, Ill., July 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2019 financial results on Friday, July 26 before the market opens.

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

TheStreet Quant Rating: C (Hold)